Thoratec seeks EU nod for HeartMate II:
This article was originally published in Clinica
Thoratec has filed an application in Europe to market its next generation heart assist device, HeartMate II, for long-term support. The application is based on data from the first 20 patients who were implanted with the device in the firm's phase I US trial and in a European study. These patients accounted for nearly 5,200 days of cumulative support and were each supported from 3-490 days. The Pleasanton, California firm said it hoped to CE-mark the device for sale this year. The HeartMate II is a left ventricular assist system for providing long-term cardiac support for patients who are in end-stage heart failure. It is currently being assessed in the US in a phase II trial, which is testing the product for both destination therapy and bridge-to-transplantation applications.
You may also be interested in...
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
The Onyx One Clear study, evaluating the Resolute Onyx drug-eluting stent in high bleeding risk patients, met its primary endpoint at the one-year follow up.